Citius Oncology Drives LYMPHIR Adoption in Cancer Care
CRANFORD, N.J., March 31, 2026 Citius Oncology, Inc. has reported strong early momentum following the U.S. launch of its...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
CRANFORD, N.J., March 31, 2026 Citius Oncology, Inc. has reported strong early momentum following the U.S. launch of its...
San Diego, USA – March 26, 2026 Crinetics Pharmaceuticals announced the submission of a Marketing Authorization Application (MAA) to...
Torrance, California | December 30, 2025 — Emmaus Life Sciences, Inc. has announced a strategic licensing and exclusive distribution...
